BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 21922652)

  • 1. Neuroblastoma progress on many fronts: the Neuroblastoma Research Symposium.
    Wylie L; Philpott A
    Pediatr Blood Cancer; 2012 Apr; 58(4):649-51. PubMed ID: 21922652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ALK is a MYCN target gene and regulates cell migration and invasion in neuroblastoma.
    Hasan MK; Nafady A; Takatori A; Kishida S; Ohira M; Suenaga Y; Hossain S; Akter J; Ogura A; Nakamura Y; Kadomatsu K; Nakagawara A
    Sci Rep; 2013 Dec; 3():3450. PubMed ID: 24356251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New insights into the genetics of neuroblastoma.
    Sridhar S; Al-Moallem B; Kamal H; Terrile M; Stallings RL
    Mol Diagn Ther; 2013 Apr; 17(2):63-9. PubMed ID: 23329364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High anaplastic lymphoma kinase immunohistochemical staining in neuroblastoma and ganglioneuroblastoma is an independent predictor of poor outcome.
    Duijkers FAM; Gaal J; Meijerink JPP; Admiraal P; Pieters R; de Krijger RR; van Noesel MM
    Am J Pathol; 2012 Mar; 180(3):1223-1231. PubMed ID: 22203052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New strategies in neuroblastoma: Therapeutic targeting of MYCN and ALK.
    Barone G; Anderson J; Pearson AD; Petrie K; Chesler L
    Clin Cancer Res; 2013 Nov; 19(21):5814-21. PubMed ID: 23965898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells.
    Schönherr C; Ruuth K; Kamaraj S; Wang CL; Yang HL; Combaret V; Djos A; Martinsson T; Christensen JG; Palmer RH; Hallberg B
    Oncogene; 2012 Dec; 31(50):5193-200. PubMed ID: 22286764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of NLRR3 orphan receptor gene is negatively regulated by MYCN and Miz-1, and its downregulation is associated with unfavorable outcome in neuroblastoma.
    Akter J; Takatori A; Hossain MS; Ozaki T; Nakazawa A; Ohira M; Suenaga Y; Nakagawara A
    Clin Cancer Res; 2011 Nov; 17(21):6681-92. PubMed ID: 21908575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MYCN and ALKF1174L are sufficient to drive neuroblastoma development from neural crest progenitor cells.
    Schulte JH; Lindner S; Bohrer A; Maurer J; De Preter K; Lefever S; Heukamp L; Schulte S; Molenaar J; Versteeg R; Thor T; Künkele A; Vandesompele J; Speleman F; Schorle H; Eggert A; Schramm A
    Oncogene; 2013 Feb; 32(8):1059-65. PubMed ID: 22484425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma.
    Zhang S; Wei JS; Li SQ; Badgett TC; Song YK; Agarwal S; Coarfa C; Tolman C; Hurd L; Liao H; He J; Wen X; Liu Z; Thiele CJ; Westermann F; Asgharzadeh S; Seeger RC; Maris JM; Guidry Auvil JM; Smith MA; Kolaczyk ED; Shohet J; Khan J
    Cancer Lett; 2016 Feb; 371(2):214-24. PubMed ID: 26683771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activated ALK collaborates with MYCN in neuroblastoma pathogenesis.
    Zhu S; Lee JS; Guo F; Shin J; Perez-Atayde AR; Kutok JL; Rodig SJ; Neuberg DS; Helman D; Feng H; Stewart RA; Wang W; George RE; Kanki JP; Look AT
    Cancer Cell; 2012 Mar; 21(3):362-73. PubMed ID: 22439933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activated Alk triggers prolonged neurogenesis and Ret upregulation providing a therapeutic target in ALK-mutated neuroblastoma.
    Cazes A; Lopez-Delisle L; Tsarovina K; Pierre-Eugène C; De Preter K; Peuchmaur M; Nicolas A; Provost C; Louis-Brennetot C; Daveau R; Kumps C; Cascone I; Schleiermacher G; Prignon A; Speleman F; Rohrer H; Delattre O; Janoueix-Lerosey I
    Oncotarget; 2014 May; 5(9):2688-702. PubMed ID: 24811913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Copy number status and mutation analyses of anaplastic lymphoma kinase (ALK) gene in 90 sporadic neuroblastoma tumors.
    Bagci O; Tumer S; Olgun N; Altungoz O
    Cancer Lett; 2012 Apr; 317(1):72-7. PubMed ID: 22085494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genes proximal and distal to MYCN are highly expressed in human neuroblastoma as visualized by comparative expressed sequence hybridization.
    Stock C; Bozsaky E; Watzinger F; Poetschger U; Orel L; Lion T; Kowalska A; Ambros PF
    Am J Pathol; 2008 Jan; 172(1):203-14. PubMed ID: 18165268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas.
    Wang Q; Hii G; Shusterman S; Mosse Y; Winter CL; Guo C; Zhao H; Rappaport E; Hogarty MD; Maris JM
    Cancer Res; 2003 Apr; 63(7):1631-5. PubMed ID: 12670915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PHOX2B-mediated regulation of ALK expression: in vitro identification of a functional relationship between two genes involved in neuroblastoma.
    Bachetti T; Di Paolo D; Di Lascio S; Mirisola V; Brignole C; Bellotti M; Caffa I; Ferraris C; Fiore M; Fornasari D; Chiarle R; Borghini S; Pfeffer U; Ponzoni M; Ceccherini I; Perri P
    PLoS One; 2010 Oct; 5(10):. PubMed ID: 20957039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ALK pERKs up MYCN in neuroblastoma.
    Lindner S; Henssen A; Astrahantseff K; Schulte JH
    Sci Signal; 2014 Oct; 7(349):pe27. PubMed ID: 25351246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hsp90 inhibition increases p53 expression and destabilizes MYCN and MYC in neuroblastoma.
    Regan PL; Jacobs J; Wang G; Torres J; Edo R; Friedmann J; Tang XX
    Int J Oncol; 2011 Jan; 38(1):105-12. PubMed ID: 21109931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Widespread dysregulation of MiRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: association of miRNA expression with survival.
    Bray I; Bryan K; Prenter S; Buckley PG; Foley NH; Murphy DM; Alcock L; Mestdagh P; Vandesompele J; Speleman F; London WB; McGrady PW; Higgins DG; O'Meara A; O'Sullivan M; Stallings RL
    PLoS One; 2009 Nov; 4(11):e7850. PubMed ID: 19924232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma.
    Moore NF; Azarova AM; Bhatnagar N; Ross KN; Drake LE; Frumm S; Liu QS; Christie AL; Sanda T; Chesler L; Kung AL; Gray NS; Stegmaier K; George RE
    Oncotarget; 2014 Sep; 5(18):8737-49. PubMed ID: 25228590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma.
    Carpenter EL; Haglund EA; Mace EM; Deng D; Martinez D; Wood AC; Chow AK; Weiser DA; Belcastro LT; Winter C; Bresler SC; Vigny M; Mazot P; Asgharzadeh S; Seeger RC; Zhao H; Guo R; Christensen JG; Orange JS; Pawel BR; Lemmon MA; Mossé YP
    Oncogene; 2012 Nov; 31(46):4859-67. PubMed ID: 22266870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.